Utah Medical Products (UTMD) Cash & Equivalents (2010 - 2026)

Utah Medical Products' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $87.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 4.9% year-over-year to $87.4 million; the TTM figure through Mar 2026 stood at $87.4 million (up 4.9% YoY), while the FY2025 annual figure was $85.8 million, up 3.35% from the prior year.
• Cash & Equivalents was $87.4 million for Q1 2026 at Utah Medical Products, up from $85.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $93.8 million in Q1 2024 to a low of $65.9 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $82.4 million across 5 years, with a median of $84.3 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents gained 27.78% in 2023, then slipped 11.17% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $75.1 million in 2022, then grew by 23.74% to $92.9 million in 2023, then fell by 10.65% to $83.0 million in 2024, then increased by 3.35% to $85.8 million in 2025, then climbed by 1.92% to $87.4 million in 2026.
• The last three Cash & Equivalents figures came in at $87.4 million (Q1 2026), $85.8 million (Q4 2025), and $84.3 million (Q3 2025), per Business Quant data.